Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Controlled Crossover Study Comparing Sugammadex and Placebo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All adult patients aged 18-80 years with American Society of Anesthesiologist (ASA) classification I-III undergoing cervical spine surgery in the prone position with intraoperative motor evoked potential monitoring.~* Operation time greater than 3 hours~Exclusion Criteria:~* Allergy to propofol or documented egg allergy~* Known allergy to sugammadex~* Severe renal dysfunction (EGFR\<30)~* British Research Medical Council (BRMC) motor grading \<3 in any peripheral muscle group preoperatively. This is inability to move the muscle group against gravity.~* Surgical requirement of strict muscle relaxation for surgical exposure~* Lack of informed consent~* Pregnancy~* Loss of MEP signals during washout period (or intraoperative spinal cord injury resulting in irreversible loss of MEP)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Initial Arm (Type: ACTIVE_COMPARATOR): The study participants will receive either Sugammadex (2 mg/kg in 10 ml 0.9% normal saline) or placebo (10 ml of 0.9% normal saline).
- Crossover Arm (Type: ACTIVE_COMPARATOR): The study participants will receive the study medication that was not given in the initial arm (either Sugammadex (2 mg/kg in 10 ml 0.9% normal saline) or placebo (10 ml of 0.9% normal saline) .

Based on this trial design, predict the completion outcome and termination type (if applicable).